What it's for (Indications)
- Alfuzosin hydrochloride extended-release tablets are specifically indicated for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH).
- BPH is a common, non-malignant enlargement of the prostate gland that can significantly impair urinary function, leading to a range of lower urinary tract symptoms (LUTS).
- These symptoms typically include hesitancy, a weak urinary stream, incomplete bladder emptying, urgency, and frequent urination, especially at night (nocturia).
- By targeting alpha-1 adrenergic receptors, alfuzosin helps to relax the smooth muscles in the prostate and bladder neck, thereby improving urine flow and reducing the obstructive symptoms.
- It is important to note that alfuzosin is not indicated for the treatment of hypertension, nor for the prevention or treatment of prostate cancer.
- The therapeutic benefits of alfuzosin in alleviating BPH symptoms contribute to an improved quality of life for affected individuals, with clinical effects generally noticeable within days to weeks of initiating therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for alfuzosin hydrochloride extended-release tablets is 10 mg administered orally once daily. To optimize absorption and minimize the risk of orthostatic hypotension, the tablet should be taken immediately after the same meal each day. It is crucial that the tablets are swallowed whole and not crushed, chewed, or divided. Altering the tablet's integrity can lead to an uncontrolled release of the active ingredient, potentially resulting in supra-therapeutic plasma levels and an increased incidence of adverse reactions. No dose titration is generally required for alfuzosin. For patients with mild to moderate renal impairment (creatinine clearance ≥ 30 mL/min), no dosage adjustment is typically necessary. However, for those with severe renal impairment (creatinine clearance < 30 mL/min) or any degree of hepatic impairment, alfuzosin should be used with extreme caution, and its administration may be contraindicated, necessitating careful clinical judgment and individual risk-benefit assessment by a healthcare professional. Strict adherence to the prescribed dosing regimen is essential for therapeutic efficacy and safety. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse reactions associated with alfuzosin hydrochloride include dizziness (occurring in approximately 6% of patients), headache (3%), and fatigue (2%).
- Other frequently observed side effects may include upper respiratory tract infection, pain, postural hypotension (especially on standing), nausea, and abdominal pain.
- More serious, albeit less common, adverse events warrant immediate attention.
- These include syncope (fainting), which can occur due to significant orthostatic hypotension, particularly following the initial dose or upon re-initiation of therapy after a lapse.
- Priapism, a prolonged and painful erection unrelated to sexual activity, is a rare but serious urological emergency that requires immediate medical intervention to prevent permanent erectile dysfunction.
- Alfuzosin has also been associated with prolongation of the QT interval in some individuals, necessitating caution in patients with pre-existing cardiac conditions or those concurrently using other QT-prolonging medications.
- Furthermore, Intraoperative Floppy Iris Syndrome (IFIS) has been reported during cataract surgery in patients currently or previously treated with alpha-1 adrenergic blockers, including alfuzosin, which can complicate surgical procedures.
Serious Warnings
- Black Box Warning: Alfuzosin hydrochloride does not carry a formal FDA Black Box Warning. However, it is imperative for healthcare professionals and patients to be fully aware of several serious warnings and precautions associated with its use, which demand careful patient selection, comprehensive education, and vigilant monitoring to ensure patient safety and optimize therapeutic outcomes. These critical safety considerations include: 1. **Orthostatic Hypotension and Syncope**: Alfuzosin can induce significant reductions in blood pressure upon standing, leading to symptoms such as dizziness, lightheadedness, and syncope (fainting). This risk is particularly high with the first dose, during dose escalation, or upon re-initiation of therapy after an interruption. The risk is further exacerbated in patients concurrently receiving antihypertensive medications, nitrates, or phosphodiesterase-5 (PDE5) inhibitors. Patients must be advised to avoid situations where injury could result from syncope and to report any such symptoms immediately. 2. **Intraoperative Floppy Iris Syndrome (IFIS)**: A serious complication, IFIS, has been observed during cataract surgery in some patients treated with alpha-1 adrenergic blocking agents, including alfuzosin, regardless of current or past use. IFIS can increase the risk of surgical complications. Patients scheduled for cataract surgery should proactively inform their ophthalmologist about their alfuzosin use. 3. **QT Interval Prolongation**: Alfuzosin has been demonstrated to prolong the QT interval in a dose-dependent manner in some patients. This electrical abnormality of the heart can lead to potentially life-threatening ventricular arrhythmias, including Torsade de Pointes, particularly in individuals with pre-existing QT prolongation, those with relevant cardiac disease, or those receiving other medications known to prolong the QT interval. Alfuzosin should be used with extreme caution in these susceptible populations. 4. **Priapism**: A rare but critical urological emergency, priapism (a prolonged, painful erection lasting more than 4 hours and unrelated to sexual activity) has been reported with alfuzosin use. Untreated priapism can result in permanent erectile dysfunction due to ischemic damage. Patients must be educated on this risk and instructed to seek immediate medical attention if an erection persists for an abnormally long duration. 5. **Drug Interactions**: Concomitant use of alfuzosin with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) is contraindicated due to a substantial increase in alfuzosin plasma concentrations, which can significantly elevate the risk of hypotension and QT prolongation. Caution is also advised when co-administering with moderate CYP3A4 inhibitors or other alpha-adrenergic blocking agents.
- Patients should be thoroughly counselled regarding the potential for orthostatic hypotension, characterized by dizziness, lightheadedness, or syncope (fainting), particularly within the first few hours after the initial dose or upon re-initiation of therapy.
- This risk is heightened in individuals concomitantly receiving antihypertensive medications, nitrates, or phosphodiesterase-5 (PDE5) inhibitors.
- It is advisable to administer alfuzosin immediately after a meal to mitigate this risk.
- Healthcare providers must be aware that alfuzosin can cause Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery; therefore, patients should inform their ophthalmologist of alfuzosin use prior to any ophthalmic procedure.
- Caution is warranted in patients with known prolongation of the QT interval or those taking medications known to prolong the QT interval, as alfuzosin itself may prolong the QT interval, potentially increasing the risk of serious ventricular arrhythmias.
- Cases of priapism (prolonged, painful erection) have been reported; patients must be instructed to seek immediate medical attention if an erection persists for more than 4 hours to prevent permanent tissue damage.
- Renal and hepatic impairment require careful consideration and may necessitate dose adjustment or contraindication.
How it Works (Mechanism of Action)
Alfuzosin operates as a highly selective antagonist of post-synaptic alpha-1 adrenergic receptors, predominantly found in the smooth muscle tissue of the prostate, prostatic capsule, bladder neck, and prostatic urethra. By selectively blocking these alpha-1 receptors, alfuzosin induces relaxation of the smooth muscle cells within these structures. This relaxation leads to a significant decrease in urethral resistance and an increase in urine flow, thereby alleviating the dynamic component of bladder outflow obstruction characteristic of benign prostatic hyperplasia (BPH). Unlike some older, less selective alpha-blockers, alfuzosin exhibits a degree of uroselectivity, meaning its primary pharmacological effects are localized to the lower urinary tract with relatively less impact on vascular alpha-1 receptors. This targeted action is believed to contribute to a reduced incidence of systemic cardiovascular side effects, such as orthostatic hypotension, compared to non-selective agents. The extended-release formulation ensures a sustained plasma concentration, providing a consistent therapeutic effect over a 24-hour period.